Ignite Creation Date:
2024-05-06 @ 10:53 AM
Last Modification Date:
2024-10-26 @ 12:37 PM
Study NCT ID:
NCT03376503
Status:
COMPLETED
Last Update Posted:
2017-12-19
First Post:
2017-12-12
Brief Title:
Nanogen Pegfilgrastim Pegcyte PKPD Clinical Study in Breast Cancer Patients
Sponsor:
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Organization:
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Study Overview
Official Title:
A Randomized Double-blind Parallel Study Comparing Pharmacokinetic PK and Pharmacodynamic PD Parameters of Pegcyte Nanogen and Reference Product Neulastim Roche for Chemotherapy-induced Neutropenia in Breast-cancer Patients
Status:
COMPLETED
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Breast cancer patients scheduled to receive myelosuppressive chemotherapy AC regimen will be enrolled in this study Eligible patients receive single SC injection of pegcyte or neulastim 24 hours after administration of chemotherapy Doxorubicin and Cyclophosphamide in the first cycle 14 days each cycle Blood samples are collected to determine the serum concentration of investigational drugs at specific time points in the first cycle Absolute neutrophil count CD34 count Cmax maximum serum concentration AUC0-t area under the curve of the plasma concentration time and Tmax time required to reach Cmax will be calculated from the serum concentration profile
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None